Share
Figure 1.
Change in FVC from Baseline of Bexotegrast 320 mg Over 12 Weeks in INTEGRIS-IPF; Mixed Model Repeat Measures Analysis – Modified Intent to Treat Population
Format
PNGSource
Pliant Therapeutics, Inc.Downloads
About Us
GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases, financial disclosures and multimedia content to media, investors, and consumers worldwide.
Follow us on social media: GlobeNewswire Linkedin Notified Twitter